Coronary Artery Disease
Conditions
Interventions
1:Bivalirudin combined with ticagrelor
2:heparin combined with ticagrelor
Sponsors
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)no restrictions on gender and age; patients with symptoms lasting >48 h in the presence of (i) electrocardiogram (ECG) evidence of ongoing ischemia (ST segment elevation of =1 mm in two or more contiguous electrocardiogram leads, or with a new left bundle branch block); (ii) ongoing or recurrent pain and dynamic ECG changes; and (iii) ongoing or recurrent pain, symptoms, and signs of heart failure, shock, or malignant arrhythmias; (2) revascularization for culprit target vessel; (3) use of antiplatelet agents (aspirin and ticagrelor, loading or maintenance dose) before PCI as per relevant guidelines;and (4)gave written informed consent.
Exclusion criteria
Exclusion criteria: (1) clopidogrel within 5 days before PCI; (2) use of heparin within 4 hours before PCI/low molecular weight heparin, sodium fondaparinux within 12 hours before PCI; (3) allergy to any of the study drugs; (4) combined with other antiplatelet drugs, (5) intravenous thrombolytic therapy; or (6) warfarin, or new oral anticoagulants within 3 months before PCI or 30 days after PCI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ???????; | — |
Countries
China
Contacts
Public ContactXiaofan Yu
Outcome results
None listed